Serum "big insulin-like growth factor II" from patients with tumor hypoglycemia lacks normal E-domain O-linked glycosylation, a possible determinant of normal propeptide processing.
about
Role of pro-IGF-II processing by proprotein convertase 4 in human placental developmentDoege-Potter syndrome: A review of the literature including a new case report.Intravenously injected insulin-like growth factor (IGF) I/IGF binding protein-3 complex exerts insulin-like effects in hypophysectomized, but not in normal rats.Concepts and principles of O-linked glycosylation.Burkitt's lymphoma presenting with lactic acidosis and hypoglycemia - a case presentation.Signalling pathways of insulin-like growth factors (IGFs) and IGF binding protein-3.Insulin-like growth factor expression in human cancer cell lines.The role of insulin-like growth factor system in soft tissue sarcomas: from physiopathology to targeted therapeutic approaches.Post-translational processing of the insulin-like growth factor-2 precursor. Analysis of O-glycosylation and endoproteolysis.Biochemical characterization of individual human glycosylated pro-insulin-like growth factor (IGF)-II and big-IGF-II isoforms associated with cancer.Prediction of O-glycosylation of mammalian proteins: specificity patterns of UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferaseA case of hepatoma associated with hypoglycaemia and overproduction of IGF-II (E-21): beneficial effects of treatment with growth hormone and intrahepatic adriamycin.Biophysical and biological properties of naturally occurring high molecular weight insulin-like growth factor II variants.Soluble insulin-like growth factor II/mannose 6-phosphate receptor carries multiple high molecular weight forms of insulin-like growth factor II in fetal bovine serum.Reversal of diabetes associated with escape of myeloma: evidence for inappropriate IGF-II secretion.
P2860
Q24534366-AFF199BD-68AC-4ED5-B051-5440176219F4Q33443391-8A538C97-00AE-46D6-AA21-B49A0EFACA9CQ34194165-3848EDB0-D6CF-45FF-BB7A-F356C3A3D3D2Q34749639-034A8CC5-DF0C-41F0-9043-119139B10494Q35994945-463D9BE3-DEF3-435A-A4D1-CB9E37D26B24Q37927102-CD97A4D3-4CD2-452E-B643-94BA29B02A58Q38357885-951A6EA1-8BBD-45BA-9BE3-C633A258DF93Q38612221-793066C5-AF76-4A16-93B3-D253521D36EDQ41026364-187D269E-5542-4177-9A2C-F543E0D06830Q41789322-DCAB6A59-6943-405E-9C84-ED478E663B4EQ42091424-40220758-8E75-489F-8377-143DD79B9F9AQ42476585-E75D6A60-FD99-4EFB-841E-731BB875C08BQ47313772-3A9EF284-F1BE-4868-985F-809317AE6BC6Q47350569-DCC636F2-2194-4239-926E-3146CB85868BQ51595670-D43EB0C0-CD54-4293-BD81-46D82EAFB73F
P2860
Serum "big insulin-like growth factor II" from patients with tumor hypoglycemia lacks normal E-domain O-linked glycosylation, a possible determinant of normal propeptide processing.
description
1993 nî lūn-bûn
@nan
1993年の論文
@ja
1993年学术文章
@wuu
1993年学术文章
@zh-cn
1993年学术文章
@zh-hans
1993年学术文章
@zh-my
1993年学术文章
@zh-sg
1993年學術文章
@yue
1993年學術文章
@zh
1993年學術文章
@zh-hant
name
Serum "big insulin-like growth ...... normal propeptide processing.
@ast
Serum "big insulin-like growth ...... normal propeptide processing.
@en
type
label
Serum "big insulin-like growth ...... normal propeptide processing.
@ast
Serum "big insulin-like growth ...... normal propeptide processing.
@en
prefLabel
Serum "big insulin-like growth ...... normal propeptide processing.
@ast
Serum "big insulin-like growth ...... normal propeptide processing.
@en
P2093
P2860
P356
P1476
Serum "big insulin-like growth ...... normal propeptide processing.
@en
P2093
R C Baxter
W H Daughaday
P2860
P304
P356
10.1073/PNAS.90.12.5823
P407
P577
1993-06-01T00:00:00Z